oral glp 1 agonist for type 2 diabetes In the phase 3 ACHIEVE-1 trial, published in June 2025, the small-molecule GLP-1 receptor orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with A new oral GLP-1 medication

By fusing GLP-1 with fatty acids for acylation, the molecular self-association is promoted, thus prolonging the diffusion time of the drug from the injection site

Expert Opin Pharmacother (2007) 8:2593608

Kushner now sees that often inverted: the drug does the heavy lifting on appetite, and lifestyle becomes the thing that makes the result last

Both medications belong to a class called incretin mimetics, but tirzepatide engages a second hormone pathway that semaglutide does not

Personalizing Treatment Based on DEXA Results Healthcare providers can use DEXA scan data to tailor GLP-1 treatment plans, including dietary, exercise, or medication adjustments to optimize body composition outcomes